Enlarging the volume of subcutaneous autoinjector solutions

SHL Medical is pleased to announce the release of its 2023 sustainability report, which details the company’s ongoing efforts and accomplishments in sustainability and innovation. 

Ready to embark on a journey where connectivity meets autoinjectors? Dive into the world of SHL Medical’s Molly® Connected Cap and experience the future of healthcare. Driven by its experience with commercializing over three dozen autoinjectors worldwide, including 17 combination product projects from the market-proven Molly modular platform technology, SHL Medical developed the Molly Connected Cap autoinjector – an agile solution that supports remote adherence monitoring for personalized care.
Explore the webpage to learn how Molly Connected Cap can help transform patients’ treatment journey: https://bitly.ws/32ZBu

SHL Medical and AARDEX Group announced their strategic partnership aimed at delivering an end-to-end solution for pharma customers seeking to demonstrate patient adherence within clinical trials.

SHL embarked on a journey of transformation with the Molly® autoinjector. After successfully supporting the development of more than a dozen combination products globally, we decide to take the innovation up a notch. 
THIS is the next generation of Molly and Molly 2.25. Built upon a modular platform technology, Molly now offers flexibility beyond a conventional platform model that spans across the development processes. 

Get an in-depth understanding of how Molly works to address the varying requirements of the industry and learn more about SHL's offerings at our website.

Visit the Molly website for more information: https://bit.ly/3FkJtzm

SHL Medical and AARDEX Group announced their strategic partnership aimed at delivering an end-to-end solution for pharma customers seeking to demonstrate patient adherence within clinical trials.

The constant evolution of drug formulations across various disease areas opens a wider avenue for subcutaneous drug delivery. SHL Medical's Maggie® is a cartridge-based autoinjector that requires just two steps to operate. Built with the market-proven Needle Isolation Technology (NIT®), the device can accommodate varying formulations with volumes up to 3 mL. Following that, SHL Medical is excited to introduce Maggie 5.0 − the newest member of our NIT device family, developed to potentially accommodate injection volumes previously not considered by traditional autoinjectors.

SHL Medical announced today the release of its Sustainability Report for 2022. The report provides a comprehensive overview of the company’s efforts to promote sustainability and outlines its commitment to a sustainable future.

From design to mass production, SHL Medical's end-to-end device development infrastructure ensures the lasting value of self-injection systems that we design and develop with our customers. Our comprehensive in-house manufacturing capabilities and expertise include every core competency and value-added services across the product lifecycle. 30 years of pioneering the drug delivery industryOver 50 combination products launchedTop 25 bio/pharmaceutical companies in partnership Over 2,000 granted patents in current portfolio

SHL Medical announces the acquisition of LCA Automation AG, a Swiss innovative automation solutions provider. The acquisition is SHL Medical’s response to the growing market demand for drug delivery solutions and will support its manufacturing operations globally, especially the upcoming Swiss manufacturing site in Zug.  

Working with leading biotechnology and pharmaceutical companies, we develop advanced drug delivery systems, including disposable and reusable injection devices and systems with fixed or variable dosing, high dose accuracy, and the ability to accommodate high volumes and high viscosities. ​
 

SHL Medical, a world-leading provider of advanced drug delivery solutions, announced that it has signed a collaboration agreement with MoonLake Immunotherapeutics, a clinical-stage biotechnology company focused on creating next-level therapies for inflammatory diseases, to develop an autoinjector for clinical and potential commercial supply of MoonLake’s Nanobody® sonelokimab based on SHL Medical’s Molly® autoinjector technology.

SHL’s CMO services were established to create added value for our partners following the successful design and development of their device, resulting in a fully integrated service from device design to commercialization.

Continuing its ambitious growth journey, SHL Medical has acquired Superior Tooling Inc., a US-based manufacturing company specializing in plastic injection molds. The integration of Superior Tooling will strengthen the SHL’s inhouse manufacturing capabilities, particularly for its upcoming US manufacturing site in North Charleston, SC, scheduled to begin operations in mid-2024.

SHL’s commitment to our partners as well as the patients they serve stems from a culture deeply rooted in our corporate vision − that of delivering quality and leadership through innovative solutions that empower people.

SHL Medical, a leading provider of drug delivery solutions worldwide, furthers its expansion strategy by acquiring SMC Mould Innovation, a Swiss manufacturer specialising in high-performance injection molding tools, based in Hallau. 

Through an ensemble of rich multimedia content introducing our expertise and capabilities, visitors will be able to see our machine systems and experts at work on developing the devices that we are so proud of.

 

SHL Medical, a world-leading provider of drug delivery devices, and ten23 health®, a leading Swiss Contract Development and Manufacturing Organization (CDMO) for sterile drugs, announced strategic partnership to provide a streamlined offering for pharmaceutical and biotech companies that require sterile drug/device combination products.

Sustainability is becoming increasingly important in the pharma and biopharma industries, with many companies working to incorporate more eco-friendly materials, minimise waste and improve social impact. One such company is SHL Medical, a producer of advanced delivery devices, who are utilising data science to advance their sustainability goals. In this podcast, we discuss the relationship between data and sustainability and hear from SHL how their data-driven approach has produced ‘win-win scenarios’ for the company, its customers and the planet.

SHL Medical, a world-leading solutions provider of advanced drug delivery systems and SteriPack Group, renowned global supplier of secondary packing and final assembly services to the pharmaceutical industry, enter a non-exclusive strategic partnership. 

The Molly® Connected Cap is a compact, retrofittable autoinjector add-on that records and transmits data on patients’ use of the device.

SHL Medical (SHL), a world-leading solutions provider of advanced drug delivery systems enters a non-exclusive strategic partnership agreement with FUJIFILM Diosynth Biotechnologies, a world-leading contract development and manufacturing organization (CDMO) for biologics, vaccines, advanced therapies and oncolytic viruses to help meet growing market demand for autoinjector medicines.

Maggie 5.0 mL is the large-volume variation of the Maggie cartridge-based autoinjector, built with SHL’s market-proven Needle Isolation Technology (NIT®).

SHL Medical, a world-leading provider of advanced drug delivery solutions, is a proud recipient of the prestigious EcoVadis® Silver Medal for its sustainability performance. The company received further recognition from the Science Based Targets initiative (SBTi) for its near-term emissions targets.

Maggie is a cartridge-based solution that accommodates fill volumes up to 3.0 mL.

The partnership between SHL Medical and Lifecore Biomedical will allow the companies to exchange knowledge and experience in their respective fields and provide their customers unparalleled guidance in CDMO services and best-in-class options for drug delivery device development.

Molly 2.25 is a large-volume variation of the Molly autoinjector, allowing it to accommodate biologics of higher volumes.

SHL Medical, a leader and front-runner in advanced technologies for autoinjectors and specialty drug delivery systems, announced the launch of a new webpage for its Molly® Connected Cap, a smart, retrofittable add-on for the market-proven Molly modular platform autoinjector.

Built on a modular platform technology, the Molly autoinjector is designed to meet the evolving requirements of future autoinjectors.

SHL Medical is forging alliances with a selection of solutions providers along the drug delivery value chain, including with primary container providers, CMOs/CDMOs, and various service providers and suppliers of primary and secondary packaging, to further strengthen its vertically integrated business model.

Explore the complete journey of autoinjectors, from initial planning to successful launch, with insights into design, development, and market readiness.

In this webinar, the speakers will help you understand the intricacies of digitalization in autoinjector manufacturing, reporting on the key learnings from implementing end-to-end digital processes – from product and process development down to the shop floor and machine monitory systems.

A retrospective analysis on how the new generation of Molly autoinjectors have incorporated a greater level of flexibility in its design and development model.

Environmental impact is an area of increasing focus for the pharma and biopharma industries, with companies like Merck, Pfizer and GlaxoSmithKline setting ambitious targets for carbon neutrality and laying plans for waste reduction.   

SHL Medical data-backed sustainability targets demonstrate the company's commitments to reducing its environmental impact across the autoinjector value chain.

SHL Medical and Innovation Zed have announced plans to launch InsulCheck® DOSE in 2022.

Built with the market-proven Needle Isolation Technology (NIT®), SHL Medical's Maggie 5.0 mL autoinjector eliminates the need for manual needle attachment.

This white paper is a retrospective analysis on how the new generation of Molly autoinjectors have incorporated a greater level of flexibility in its design and development model.

SHL Medical announced the launch of its Molly autoinjector webpage.

The Innovation Partnership program enables SHL Medical and its pharma partners to co-develop connected solutions through an agile approach.

SHL’s Molly® and Molly® 2.25 mL autoinjectors are built upon a proven modular platform technology to support shorter development timelines and increased flexibility in device design and production.

SHL Medical is championing its global expansion journey by leveraging the Industry 4.0 technologies.

SHL Medical hits two sustainability milestones, propelling the company into the top 8% among industry leaders in the drug delivery sector.

In this presentation, we introduce our most recent development – a versatile, reusable, and connected electromechanical solution that upholds the concept of drug agnosticism, platform flexibility, ease-of-use, as well as device programmability. By leveraging technological application expertise, we demonstrate how an electromechanical, versatile device platform can flexibly host different primary containers and formulations. Here, we also demonstrate how adding programmable firmware into the device circumvents formulation uncertainties across the pre-clinical, clinical, and commercial development of the drug counterpart. Finally, we show how the conserved element of the device results into an autoinjector solution that flexibly addresses various primary containers, therapy areas, regional healthcare landscapes, as well as patient groups. We also discuss an optional function for tracking injection-related data, opening pathways to gather detailed insights into the patient experience, and ultimately opening possibilities to connect such device usage data with other digital health solutions.

Abstract: Digital health solutions create myriad possibilities in terms of enabling “beyond the pill” health outcomes. However, the path to streamlining a strategic approach between pharma and its development partners toward creating smart combination products remains a challenge. With a general consensus that developers must accurately determine in advance what users want, many companies wait upon the success of early players as a determinant to foray into digital health. This philosophy, however, disregards the heterogeneity of combination products in development along with the diversity of clinical or patient-reported outcomes measures. Here, we present a dissection of SHL’s Innovation Partnership program along with our connected device offering – both of which allows us to flexibly collaborate with any pharmaceutical partner in the development of connected therapeutics.